News | January 31, 2022
Cipla has strong traction in India and the US: ICICI Direct
ICICI Direct’s analysis of Cipla’s Q3FY22 results
ICICI Direct’s analysis of Cipla’s Q3FY22 results
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer
Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
The new centre will comprise a team of 50 highly experienced specialists
Direct to consumer pharmacy and formation as pharmacy benefit manager further mission to drastically expand access to affordable pharmaceuticals
It meets stringent requirements for ensuring the safe storage and efficacy of temperature-sensitive vaccines, including those for Covid-19
The company develops sustainable botanical materials for agricultural and pharmaceutical applications
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Subscribe To Our Newsletter & Stay Updated
